Amicus (FOLD) Therapeutics announced that Japan’s Ministry of Health, Labour and Welfare, MHLW, has approved Pombiliti + Opfolda for the treatment of adult patients with late-onset Pompe disease, LOPD. “We are delighted that we will now be able to offer a compelling new treatment option to patients living with late-onset Pompe disease in Japan. We are grateful to the MHLW and to Japan’s Pompe community, including the patients, families, and physicians who participated in our clinical studies, for their collaboration,” said Bradley Campbell, President and Chief Executive Officer, Amicus Therapeutics, Inc.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FOLD:
- Amicus Stockholders Approve Directors and Equity Plan
- Amicus announces publication of post-hoc analysis of data from PROPEL study
- Amicus price target raised to $22 from $21 at UBS
- Amicus Positioned for Growth with Strategic Licensing and Promising FSGS Treatment
- Amicus Therapeutics Reports Strong Q1 2025 Growth